| Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. | |
| | |
MedLine Citation:
|
PMID: 19698902 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: There is ongoing debate about the safety of selective serotonin reuptake inhibitors (SSRIs) and other serotonergic/noradrenergic antidepressants when used during pregnancy. OBJECTIVE: This article reviews the available literature on the main safety concerns associated with the use of SSRIs and other serotonergic/noradrenergic antidepressants (serotonin-norepinephrine reuptake inhibitors, norepinephrine reuptake inhibitors, noradrenergic and specific serotonergic antidepressants) during pregnancy. METHODS: English-language reports of analytical and descriptive studies, including case reports, case series, and meta-analyses, were identified through searches of MEDLINE, EMBASE, and PsycINFO (1966-April 2009). The search terms were fluoxetine, paroxetine, sertraline, Citalopram, escitalopram, fluvoxamine, venlafaxine, mirtazapine, reboxetine, duloxetine, SSRI, SNRI, NaSSA, and NRI in association with depression, pregnancy, prenatal exposure, miscarriage, spontaneous abortion, malformation, in utero exposure, and neonatal complications. RESULTS: Paroxetine has been associated with significant risks of major malformation, particularly cardiac defects, when used during pregnancy. Significant associations between maternal exposure to SSRIs and both persistent pulmonary hypertension of the newborn and a self-limiting neonatal behavioral syndrome have been reported in a number of recent original studies and meta-analyses. Some studies have suggested a relationship between the use of SSRIs or other serotonergic/noradrenergic antidepressants and the occurrence of miscarriage, although these studies had methodologic limitations that affected the strength of the data. Evidence for a possible association between in utero exposure to SSRIs or other serotonergic/noradrenergic antidepressants and alterations in neurobehavioral development, bleeding, and QTc-interval prolongation is currently weak. CONCLUSION: The available evidence suggests that SSRIs and other serotonergic/noradrenergic antidepressants should be used with caution during pregnancy, with careful follow-up of infants exposed to these agents in utero. |
| | |
Authors:
|
Marco Tuccori; Arianna Testi; Luca Antonioli; Matteo Fornai; Sabrina Montagnani; Narcisa Ghisu; Rocchina Colucci; Tiberio Corona; Corrado Blandizzi; Mario Del Tacca |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinical therapeutics Volume: 31 Pt 1 ISSN: 1879-114X ISO Abbreviation: Clin Ther Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-08-24 Completed Date: 2009-11-09 Revised Date: 2010-02-02 |
Medline Journal Info:
|
Nlm Unique ID: 7706726 Medline TA: Clin Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 1426-53 Citation Subset: IM |
Affiliation:
|
Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abnormalities, Drug-Induced Depression / complications, drug therapy* Female Humans Neurotransmitter Uptake Inhibitors / adverse effects*, therapeutic use Norepinephrine / metabolism Pregnancy Pregnancy Complications / drug therapy* Serotonin Uptake Inhibitors / adverse effects*, therapeutic use Teratogens |
| Chemical | |
Reg. No./Substance:
|
0/Neurotransmitter Uptake Inhibitors; 0/Serotonin Uptake Inhibitors; 0/Teratogens; 51-41-2/Norepinephrine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, ...
Next Document: Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the m...